Skip to main content
. 2015 Apr 23;7(1):3–8. doi: 10.1111/1759-7714.12264

Table 2.

Efficacy of first line treatment in 19 patients with stage IV lung adenocarcinoma

Group crizotinib (n = 7) Group chemotherapy (n = 12)
Case available for evaluation 6 12
CR 0 0
PR 5 (83.3%) 3 (25.0%)
SD 1 (16.7%) 6 (50.0%)
PD 0 3 (25.0%)
ORR 5/6 (83.3%) 3/12 (25.0%)
DCR 6/6 (100.0%) 9/12 (75.0%)
Case unavailable for evaluation. 1 0

CR, complete response; DCR, disease control rate; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.